Now I have a thorough understanding of the paper. Let me produce the final consolidated review.

## Summary

EMOE proposes a method for improving confidence-based rejection (OOD detection via selective classification) by: (1) generating OOD-like training points via latent-space scaling and decoding, (2) using "Extrapolatory Directional Mining" (trial-based filtering) to select which expanded points to pseudo-label, and (3) training a multi-headed MLP to match individual base-expert predictions on both original and expanded data. Experiments on 7 molecular property prediction benchmarks (ChEMBL/TDC/DrugOOD) show consistent AUPRC@R<0.2 improvements over strong baselines (D-BAT, AdvStyle, EoA, Mixup) on most datasets, with ablations confirming the value of per-expert matching and the trial-based filtering.

## Strengths

1. **Novel expansive augmentation in latent space (Sec. 3.1, Eq. 1).** Scaling latent vectors away from the origin and decoding is a clean, modality-agnostic way to generate points outside the training support, filling an underexplored niche in single-source OOD generalization.

2. **Per-expert matching is genuinely effective (Table: architecture ablation).** The ablation shows EMOE's per-head matching (ΔAUPRC@R<0.2 = 1.11) substantially outperforms both single-headed mean-matching (0.59) and multi-headed mean-matching (0.25). This is the strongest piece of evidence that the specific EMOE design matters, not just the multi-headed architecture.

3. **Strong empirical results on most benchmarks.** On 5 of 7 datasets, EMOE achieves the best AUPRC@R<0.2 (e.g., 95.18 on hERG vs 94.49 next-best; 98.95 on A549_cells vs 98.29 next-best; 96.38 on cyp_2D6 vs 94.96 next-best). EMOE also consistently improves over its own base experts on nearly every metric.

4. **Useful diversity analysis (Fig. 3).** The correlation analysis showing EMOE heads agree with base experts on correct OOD predictions but diverge on incorrect ones provides intuitive validation for why the ensemble-of-heads-plus-experts formulation works.

## Weaknesses

### Major

1. **Overclaimed "state-of-the-art" without acknowledging the DrugOOD core ec50 test counterexample.** The abstract and contributions claim "superior performance" and "state-of-the-art" broadly. However, on DrugOOD core ec50 test, D-BAT achieves 84.35 AUPRC@R<0.2 vs EMOE's 70.68 — a substantial gap in the opposite direction. While EMOE wins on most benchmarks, the paper does not acknowledge or discuss this failure case anywhere. Acknowledging limitations honestly would strengthen credibility. *(Verified: Table 2, lines 259–264; claim lines 5, 41.)*

2. **The augmented data are not validated for the actual data modality (binary molecular fingerprints).** The paper uses PCA (128 components) on 1024-bit binary ECFP4 fingerprints, scales latent codes by (1+|ε|), and "decodes" via the PCA pseudo-inverse. The decoded vectors are continuous-valued, not binary fingerprints. The paper provides no analysis showing these points are chemically plausible, that they actually fall outside the training support in the input space, or how the continuous reconstructions interact with training an MLP originally designed for binary inputs. The footnote (line 102) suggesting one could avoid the decoder does not resolve this, since all experiments use the decoder path. This gap makes it unclear whether improvement comes from exposure to meaningful OOD-like molecules or from noise injection / regularization. *(Verified: lines 94–101, 194–195, 242.)*

### Minor

3. **Directional Mining (Algorithm 1) lacks hyperparameter sensitivity analysis.** The algorithm introduces T (trial directions), M (top trials kept), q (quantile threshold), the trial model choice, and the metric ρ. The main text defers these to the appendix and provides no sensitivity analysis. The ablation (Table: trial-based filtration) compares the full method to only one alternative (confidence-based expansion, Δ=1.11 vs 0.93 at R<0.2), which is a modest margin. A sensitivity study on at least one dataset would substantiate the algorithm's claimed necessity. *(Verified: lines 107–144, 349–358.)*

4. **The PCA "decoder" is never specified.** The Method section describes the augmentation with an autoencoder framing (encoder φ, decoder γ), but the experiments use PCA with 128 components. How the PCA reconstruction (γ) is implemented — presumably via the pseudo-inverse of the loadings — is not stated. Also unclear is whether the reconstructed continuous-valued vectors are directly fed to the MLP (trained on binary ECFP4 inputs) or thresholded/binarized. This ambiguity makes it difficult to reproduce the method exactly. *(Verified: lines 94–95, 194–195.)*

5. **Diversity and prediction-correction analyses (Figs. 3, 4) are qualitative.** The scatter plot and correlation analysis are suggestive but would benefit from quantitative measures such as calibration curves on OOD data or reliability diagrams. This does not affect the core empirical claims, which rest on the AUPRC tables.

### Trivial

6. **The theoretical motivation connecting the loss to bias/variance decomposition (Sec. 3.3, Eq. 2–4) is loosely coupled to the actual method design.** The paper presents it as "high-level intuition" and the expanded points are treated as a proxy for P_out without justification. This section adds little and could be condensed without loss.

## Nice-to-Haves

- **Computational cost discussion.** EMOE uses 1024 base experts + a 1024-head MLP. A brief runtime/memory analysis would help practitioners assess deployability.
- **Ablation on number of experts/heads.** The paper fixes 1024; showing performance with fewer (e.g., 128, 256, 512) would clarify the trade-off.
- **Analysis of augmented points** (distance to nearest ID neighbor, density estimates, or nearest-neighbor reconstruction to a real molecule) would directly address Weakness 2.

## Removed Points

- **"Missing single XGBoost baseline."** The paper's EMOE base is already an XGBoost ensemble; a single XGBoost would be strictly weaker. Since EMOE improves over EMOE base (which itself beats all other baselines), this comparison would not change any conclusion. Per the rules, asymmetries favoring baselines are acceptable. **Removed.**
- **"Trial model specification is too vague."** The paper describes it as "a simple parametric model (e.g., a linear logistic-regression model)" — this is specific enough for a trial/filtering step. Hyperparameter values are deferred to the appendix (a standard practice). **Downgraded** (already covered by Weakness 3 above, but not vague).
- **"The theoretical connection is strained."** The paper presents this as "high-level hypotheses" and the reviewer admits it is "not essential to the contribution." **Downgraded to Trivial.** 
- **Formatting/style nitpicks, parser artifacts.** **Removed per rules.**

## Novel Insights

None beyond the paper's own contributions. The per-expert matching ablation (outperforming mean-matching by a large margin) is the most informative result in the reviews — it cleanly shows that the key to EMOE's success is matching each expert individually rather than averaging their predictions.

## Suggestions

1. **Acknowledge the DrugOOD core ec50 test limitation explicitly** and discuss why the method might struggle on that specific benchmark (e.g., the size-based split creates a harder extrapolation task, or D-BAT's diversity-enforcement is better suited to that distribution shift). This honesty would significantly strengthen credibility.

2. **Provide an empirical analysis of the augmented points**, even a basic one: report the distribution of reconstruction errors (L2 distance between original and decoded point), the fraction of decoded bits that are non-binary, and the distance to nearest ID training point in the input space. This would directly address the core concern about augmentation validity.

3. **Add a sensitivity analysis for the Directional Mining hyperparameters** (q, T, M) on at least one dataset, and report the default values used in the main experiments.

4. **Specify the PCA decoder implementation** (e.g., matrix pseudo-inverse) and clarify how continuous decoded vectors are handled by the MLP.

## Score and Decision

**Originality:** The combination of latent-space scaling for augmentation, trial-based filtering, and per-expert matching is novel.  
**Importance:** Improving OOD rejection is practically important, especially for drug discovery applications.  
**Claims support:** Mostly supported, but the "SOTA" claim overreaches (one clear counterexample ignored) and the augmentation mechanism lacks validation.  
**Soundness:** Empirical methodology is sound overall (multiple benchmarks, ablations, standard deviations).  
**Clarity:** The main ideas are clearly communicated, though the PCA/decoder ambiguity needs resolution.  
**Value:** The multi-headed matching strategy and the augmentation idea are likely to inspire follow-up work.

MY FINAL SCORE: <pineapple>6.0</pineapple>
MY FINAL DECISION: <orange>Accept</orange>